|

The
Virtual Phenotype
A third approach to resistance
testing is the "virtual" phenotype. This assay, developed
by Virco, is really a genotype resistance that is interpreted with
the aid of a large database of samples with paired genotypic and
phenotypic data. Viruses with genotypes that are similar to the
patient's virus are identified by searching the database, and the
average IC50 of these matching viruses is calculated. This information
is then used to estimate the likely phenotype of the patient's virus.
Since the database currently has >18,000 paired genotypes and
phenotypes, there is a high likelihood that a large number of matches
can be found for most genotypes encountered in practice. The actual
and virtual phenotype show excellent correlation (r2>0.8) for
most drugs (15). Moreover, retrospective
analysis of samples from the VIRA 3001 study (see below) showed
that the VirualPhenotype performed as well as the actual phenotype
in predicting response to treatment (16).
Several studies are underway to test the performance of the VirtualPhenotype
in patient management.
The VirtualPhenotype
has important strengths and weaknesses. The main strength of this
approach is that it reduces complex genotypic data to simple phenotypic
categories based on a rational, data-driven analysis of similar
genotypes. Reports indicate the number of matches, and the proportion
of sensitive and resistant viruses among the matches. It is important
to remember, however, that the virtual phenotype only provides an
estimate of the probable phenotype of the patient's virus-the actual
phenotype could be more or less sensitive than the average value
obtained from the database. The main weakness of this approach is
that the confidence placed in the result depends on the number of
matches, and on picking the right codons to incorporate into the
database search. Correlation between actual and virtual phenotype
will be weaker for newer drugs or in cases where there are fewer
matches due to unusual genotypes. Also, the virtual phenotype may
place undue emphasis on using genotypes to predict phenotype, rather
than treatment outcome.
4/15/01
Copyright 2001
by HIV and Hepatitis.com. All Rights Reserved
|
 |